No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy

J Infect Dis. 2010 Jan 15;201(2):293-6. doi: 10.1086/649569.

Abstract

Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9 experienced virologic suppression and continued enfuvirtide-containing therapy for at least 48 weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831 .).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / virology*
  • Drug Therapy, Combination
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV-1 / physiology*
  • Humans
  • Male
  • Peptide Fragments / therapeutic use*
  • Viral Load
  • Virus Latency / drug effects*

Substances

  • Antiviral Agents
  • HIV Envelope Protein gp41
  • Peptide Fragments
  • Enfuvirtide

Associated data

  • ClinicalTrials.gov/NCT00051831

Grant support